The Programme for Global Paediatric Research

M Manley1, A Zipursky

  • 1The Programme for Global Paediatric Research, Dept of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. margaret.manley@sickkids.ca

Insights

Millions of children in low- and middle-income countries (LMICs) die from preventable diseases like malaria and tuberculosis. Research funding disproportionately favors diseases affecting high-income populations, neglecting urgent global health needs.

Area of Science:

  • Global Health
  • Epidemiology
  • Pediatric Diseases

Background:

  • Millions of children in low- and middle-income countries (LMICs) face high mortality rates from infectious and neonatal diseases.
  • Significant progress has been made in understanding and treating these conditions.
  • However, a disparity exists in research focus and funding.

Purpose of the Study:

  • To highlight the disproportionate allocation of research efforts towards diseases prevalent in high-income countries.
  • To underscore the urgent need for increased research into diseases affecting LMICs.
  • To advocate for a more equitable distribution of global health research funding.

Main Methods:

  • Analysis of global health research funding trends.
  • Review of disease burden statistics in LMICs versus high-income countries.
  • Literature review on research priorities and outcomes.

Main Results:

  • Research funding is heavily skewed towards diseases primarily affecting high-income populations.
  • Diseases causing millions of deaths in LMICs, such as malaria, tuberculosis, and neonatal disorders, receive comparatively less research attention.
  • This imbalance limits the development of effective interventions for the most vulnerable populations.

Conclusions:

  • A significant gap exists in global health research, with underfunding of diseases prevalent in LMICs.
  • Addressing this disparity is crucial for reducing child mortality and improving global health equity.
  • Increased investment and focused research are urgently needed for diseases impacting millions in LMICs.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...